Each year, Nature Biotechnology highlights companies that have received sizeable early-stage funding in the previous year. Switch Therapeutics is rethinking cell-type specificity, building precision RNAi therapeutics for the brain.
Enjoying our latest content?
Log in or create an account to continue
- Access the most recent journalism from Nature's award-winning team
- Explore the latest features & opinion covering groundbreaking research
or
References
Han, S.-p et al. Mol. Ther. Nucleic Acids 27, 797–809 (2022).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Marchal, I. Editor’s pick: Switch Therapeutics. Nat Biotechnol 42, 1486–1487 (2024). https://doi.org/10.1038/s41587-024-02423-9
Published:
Issue date:
DOI: https://doi.org/10.1038/s41587-024-02423-9
